<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 16 Jul 2026 14:59:55 -0400--><rss version="2.0">
    <channel>
        <title>Intensity Therapeutics, Inc. (INTS) Press Releases</title>
        <link>https://ir.intensitytherapeutics.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/intensitytherapeutics/files/theme/images/logo-sm.png</url>
                <title>Intensity Therapeutics, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/128/intensity-therapeutics-inc-restarts-patient-treatment-in</link>
                <pubDate>Wed, 15 Jul 26 07:45:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/128/intensity-therapeutics-inc-restarts-patient-treatment-in</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/127/intensity-therapeutics-provides-mid-year-update</link>
                <pubDate>Wed, 01 Jul 26 08:00:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/127/intensity-therapeutics-provides-mid-year-update</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/126/intensity-therapeutics-recognized-with-ghp-magazines-2026</link>
                <pubDate>Thu, 14 May 26 08:00:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/126/intensity-therapeutics-recognized-with-ghp-magazines-2026</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/125/intensity-therapeutics-reports-first-quarter-2026-financial</link>
                <pubDate>Thu, 07 May 26 16:06:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/125/intensity-therapeutics-reports-first-quarter-2026-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/124/intensity-therapeutics-recognized-with-pinnacle-award-for</link>
                <pubDate>Wed, 15 Apr 26 09:15:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/124/intensity-therapeutics-recognized-with-pinnacle-award-for</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/123/intensity-therapeutics-reports-2025-year-end-financial</link>
                <pubDate>Fri, 27 Mar 26 16:12:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/123/intensity-therapeutics-reports-2025-year-end-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/122/intensity-therapeutics-strengthens-ip-portfolio-with</link>
                <pubDate>Tue, 24 Mar 26 08:00:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/122/intensity-therapeutics-strengthens-ip-portfolio-with</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/121/intensity-therapeutics-inc-provides-update-on-the-phase-2</link>
                <pubDate>Thu, 12 Mar 26 07:30:00 -0400</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/121/intensity-therapeutics-inc-provides-update-on-the-phase-2</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/120/intensity-therapeutics-regains-compliance-with-nasdaqs</link>
                <pubDate>Fri, 06 Mar 26 07:47:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/120/intensity-therapeutics-regains-compliance-with-nasdaqs</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Intensity Therapeutics Announces Reverse Stock Split]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/119/intensity-therapeutics-announces-reverse-stock-split</link>
                <pubDate>Fri, 13 Feb 26 08:58:00 -0500</pubDate>
                <guid>https://ir.intensitytherapeutics.com/news-events/press-releases/detail/119/intensity-therapeutics-announces-reverse-stock-split</guid>
                                                                            </item>
            </channel>
</rss>